Contact Us
Drug Search Results
More Filters [+]

Vemircopan

Alternative Names: vemircopan, ach-0145228, ach0145228, ach 0145228, ach-5228, ach5228, ach 5228, alxn-2050, alxn 2050, alxn2050
Latest Update: 2024-10-02
Latest Update Note: Clinical Trial Update

Product Description

Vemircopan is an orally bioavailable inhibitor of complement factor D (FD; CFD), a serineprotease that cleaves complement factor B, with potential complement system inhibiting activity. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Vemircopan)

Mechanisms of Action: CFD Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vemircopan

Countries in Clinic: Argentina, Australia, Brazil, China, Germany, Israel, Italy, Korea, Mexico, Peru, Serbia, South Korea, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 11

Highest Development Phases

Phase 2: Glomerulonephritis|IgA Nephropathy|Kidney Diseases|Lupus Nephritis|Myasthenia Gravis

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ALXN2050-NEPH-201

P2

Unknown Status

IgA Nephropathy|Lupus Nephritis

2028-07-31

ALXN2050-NEPH-201

P2

Active, not recruiting

IgA Nephropathy|Lupus Nephritis

2026-07-11

ALXN2050-NEPH-201

P2

Active, not recruiting

Glomerulonephritis|Kidney Diseases|Lupus Nephritis|IgA Nephropathy

2026-06-30

-

P2

Active, not recruiting

Myasthenia Gravis

2025-01-10

Recent News Events

Date

Type

Title

06/11/2024

News Article

 Nimble Announces Formation of a World-Class Scientific Advisory Board

10/13/2023

News Article

 US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead

11/30/2022

News Article

 AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022

07/30/2020

News Article

 Alexion Reports Second Quarter 2020 Results

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions